文献速递产科母胎医学

重新审视Meis试验的假阳性结果证据

Re-examining the Meis Trial for Evidence of False-Positive Results.
PubMed 文献 · Obstet Gynecol · 2020-01-01

本文评论重新审视了美国FDA于2011年基于Meis试验有条件批准17α-羟孕酮己酸酯用于降低复发性早产的原始里程碑试验,并对比了未能证实原结论的PROLONG试验。作者认为Meis试验设计严谨、结果具有高度统计学显著性,不应被PROLONG的阴性结果所削弱,并断言PROLONG因实际早产率低于预期而把握度不足,属假阴性研究而非Meis试验为假阳性。

要点

  • Meis试验设计严谨,结果具有高度统计学显著性,不应被PROLONG阴性结果削弱。
  • 作者认为PROLONG因实际早产率低于预期而把握度不足,属假阴性研究。
  • 美国早产率居世界前列且PROLONG入组主要在美国境外,不应草率否定Meis试验。

核心结论

  • 作者认为Meis试验设计严谨、结果高度显著,不应被PROLONG阴性结果削弱,PROLONG属假阴性研究而非Meis试验为假阳性。

研究设计与样本

  • 本文为评论性文章,重新审视了促成FDA于2011年有条件批准17α-羟孕酮己酸酯的原始Meis试验,并对比了PROLONG试验。

主要发现

  • Meis试验设计严谨、实施规范,结果具有高度统计学显著性。
  • PROLONG试验未能证实Meis试验的原始发现,作者认为其因实际早产率低于预期而把握度不足。
  • PROLONG入组主要在美国境外,而美国早产率居世界前列。

关键数值与推荐

  • FDA于2011年基于Meis试验有条件批准17α-羟孕酮己酸酯用于降低复发性早产。
  • Meis试验由母胎医学单位网络开展,由尤妮斯·肯尼迪·施赖弗国家儿童健康与人类发展研究所资助。

临床怎么用

  • 作者认为将PROLONG结果不恰当地置于Meis试验之上会对高危孕妇造成损害。
  • 作者指出17α-羟孕酮己酸酯退出美国市场可能对公共卫生产生重大影响,需审慎评估两项试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

U.S. Food and Drug Administration (FDA)-approved 17α-hydroxyprogesterone caproate therapy is currently available to reduce recurrent preterm birth in the United States. This commentary reviews the original landmark Meis trial ("Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate"), which led to conditional approval of 17α-hydroxyprogesterone caproate by the FDA in 2011. The recent PROLONG (Progestin's Role in Optimizing Neonatal Gestation) trial failed to confirm the original findings. The Meis trial was rigorously designed and conducted, with highly statistically significant results that should not be undermined by the negative results of PROLONG. Given that the United States has among the highest preterm birth rates in the world and that the predominant enrollment in PROLONG was outside the United States, the results of the "old" Meis trial should not be summarily dismissed. It would be detrimental to high-risk pregnant patients to inappropriately prioritize results of PROLONG over the Maternal-Fetal Medicine Units Network's Meis trial (funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development). We assert PROLONG was underpowered, based on substantially lower observed preterm birth rates than anticipated, and therefore was a false-negative study, rather than the Meis trial being a false-positive study. Careful assessment of these two trials is critical as removal of 17α-hydroxyprogesterone caproate from the U.S. marketplace may have substantial effects on public health.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sibai B, Saade GR, Das AF, et al. Re-examining the Meis Trial for Evidence of False-Positive Results. Obstet Gynecol. 2020. PMID: 32769653. doi:10.1097/AOG.0000000000003991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。